ketobemidone
Sign in to saveKetobemidone, sold under the brand name Ketogan (a mixture of ketobemidone and Spasmolytic A29) among others, is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone. This may make it useful for some types of pain that do not respond well to other opioids. It is marketed in Denmark, Iceland, Norway. Until 2024 it was available in, but is now withdrawn in Sweden. It is used for severe pain.
Key facts
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 461742319
- Drug.image
- Ketobemidone skeletal formula based on xtal 1993.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 150px
- Drug.image2
- Ketobemidone ball-and-stick model from xtal 1993.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 200px
- Drug.tradename
- Ketogan
- Drug.routes_of_administration
- By mouth, rectal, intravenous
- Drug.ATC_prefix
- N02
- Drug.ATC_suffix
- AB01
- Drug.legal_AU
- S9
- Drug.legal_BR
- F1
- Drug.legal_CA
- Schedule I
- Drug.legal_DE
- Anlage II
- Drug.legal_US
- Schedule I
via Wikipedia infobox
Research
194 papers- Ketobemidone prodrugs for buccal delivery.Acta pharmaceutica Nordica · 1991
- Opioids: A Review of Pharmacokinetics and Pharmacodynamics in Neonates, Infants, and Children.European journal of drug metabolism and pharmacokinetics · 2019
- Ketobemidone is a substrate for cytochrome P4502C9 and 3A4, but not for P-glycoprotein.Xenobiotica; the fate of foreign compounds in biological systems · 2005
- [From ketobemidone to morphine or oxycodone].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke · 2016
- Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord.Neuroscience letters · 1995
via PubMed
Article
7 sectionsContents
- History
- Pharmacology
- Metabolism
- Chemistry
- See also
- References
- External links
Ketobemidone, sold under the brand name Ketogan (a mixture of ketobemidone and Spasmolytic A29) among others, is a powerful synthetic opioid painkiller. Its effectiveness against pain is in the same range as morphine, and it also has some NMDA-antagonist properties imparted, in part, by its metabolite norketobemidone. This may make it useful for some types of pain that do not respond well to other opioids. It is marketed in Denmark, Iceland, Norway. Until 2024 it was available in, but is now withdrawn in Sweden. It is used for severe pain.
==History== Ketobemidone was first synthesized in 1942 by Eisleb and colleagues, at the laboratory of I.G. Farbenindustrie at Hoechst during the Second World War. The first study of it in humans was published in 1946, and it was introduced in clinical medicine shortly after. It was not in clinical use in the United States when the Controlled Substances Act 1970 was promulgated and was assigned to Schedule I with an ACSCN of 9628. As of 2013, no annual manufacturing quota was assigned by the DEA.
Connections
Categories
3-Hydroxyphenyl compounds4-PhenylpiperidinesAnalgesicsDrugboxes which contain changes to verified fieldsDrugboxes which contain changes to watched fieldsDrugs with non-standard legal statusECHA InfoCard ID from WikidataEuphoriantsKetonesMu-opioid receptor agonistsNMDA receptor antagonistsSynthetic opioids